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that circulate at varying concentrations in the blood. Rather than reporting the abso-
lute concentration of the circulating factors (as is done with most chemistry analytes),
the clinical laboratory reports activities for most coagulation factors (ie, the functional
activity of the factor in the patient’s plasma compared with that of calibrator or a stan-
dard plasma, the latter with a defined assayed activity of 100%).
Factor deficiencies traditionally are classified as type 1 or type 2. In type 1 defi-
ciency, the protein structure of the factor is normal, but there is a decreased concen-
tration in the circulation, so the activity level is decreased. This can be caused by
increased clearance or decreased production of the factor. Essentially all acquired
and many inherited disorders fall into this category. In type 2 deficiencies, there is
a normal or nearly normal concentration of a circulating protein that is intrinsically
defective and therefore also demonstrates a lower overall activity level. Either typeThis work was supported in part by a grant from Blood Systems Inc.
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ARTICLE IN PRESSof deficiency will show decreased activity when measured by laboratory assays. When
measuring the protein itself using an antigen assay, type 2 deficiencies show a relative
preservation of the antigen level in relation to the activity level, while type 1 deficiency
also shows decreased antigen. This situation is illustrated best in von Willebrand
disease (vWD) (see article by Torres in this issue).
A brief survey of the clinical aspects of the inherited and acquired factor deficiencies
is presented first, followed by a discussion of the laboratory considerations in evalu-
ating patients who have possible factor deficiencies. Table 1 and Box 1 illustrate
the etiologies, relative incidence, and other characteristics of the various factor defi-
ciencies discussed. Some deficiencies of proteins involved in hemostatic regulation
also will lead to bleeding diatheses (eg, alpha-2-antiplasmin); however, these abnor-
malities are not within the scope of this article.
INHERITED FACTOR DEFICIENCIES
Inherited bleeding disorders have been recognized since ancient times, often caused
by severe bleeding with circumcision or minor trauma. Severe hemophilia A and B,
and severe F11 deficiency typically prolong the patient’s activated partial thrombo-
plastin time (aPTT), but this abnormality is not always overwhelming. Many patients
present with an aPTT between the upper end of the normal reference range and the
middle of the typical aPTT heparin reference range. Deficiencies of the contact
factors—most commonly F12—can prolong the aPTT more significantly, similar to
what is seen with a high level of therapeutic heparin or heparin contamination after
blood is drawn through a heparinized line. Hemophilia A (F8 deficiency) and B (F9 defi-
ciency) are the only factor deficiencies typically inherited in a sex-linked pattern.
Sufficient hemostasis often can be achieved despite having coagulation factor
levels below the normal laboratory reference ranges. Similarly, a modest increase in
the endogenous circulating factor activity level (eg, from 0.5% to 5%) in hemophilia
can have major clinical implications, essentially converting a severe to a mild pheno-
type. This provides hope to researchers working to use gene therapy as a possible
treatment of inherited hemophilia.1
Factor 8 Deficiency (Hemophilia A)
Hemophilia A2 is the most common inherited factor deficiency. This X-linked disorder
is caused by a deficiency of F8. F8 is the cofactor that works with F9 to activate F10,
increasing the reaction rate by several orders of magnitude. Older nomenclature calls
the F8 coagulant activity ‘‘VIII:C’’ and the measurement of the antigen ‘‘VIII:Ag.’’ The
F8 molecule usually circulates in the bloodstream, protected from degradation by
forming a stable complex with von Willebrand factor (vWF). Deficiency of vWF leads
to increased clearance of F8 from the circulation; therefore, F8 activity typically is
included in screening panels for vWD.
Many different genetic mutations have been classified in various hemophilia A pedi-
grees.3,4 Mild and moderate hemophilias typically are caused by one of many
missense mutations induced by single base pair substitutions. Severe hemophilia A,
by contrast, is caused more often by larger gene defects, including inversions (intron
22), large deletions, and insertions. Thus, both activity and antigenic protein measures
are typically very low. Intrachromosomal intron–exon recombinations of the X chromo-
some account for about half of the severe forms. For the prenatal genetic diagnosis of
knownmales to be effective, family studies must identify the mutation particular to that
pedigree. There is a high sporadic occurrence (high spontaneous mutation rate),
however, of hemophilia also; thus, about 30% of newly diagnosed severe hemophiliaCLL469_proof  13 June 2009  2:22 pm
Table 1
Congenital factor deficiencies
Factor Deficiency Estimated Incidence Inheritance Pattern/Genes Involved Bleeding Severity
F8 (hemophilia A) 1:10,000 X-linked recessive (Xq28) Mild >5%
Moderate (1% to 5%)
Severe (<1%)
F9 (hemophilia B) 1:30,000 X-linked recessive (Xq27) Mild to severe
F11 Rare, 5% in Ashkenazi Jews Autosomal recessive (4q32q3) Mild to severe
F2 (prothrombin) Rare Autosomal recessive (11p11–q12) Mild to moderate
F5 1:1 million Autosomal recessive (1q21–q25) Mild to moderate
F7 1:500,000 Autosomal recessive (13q34) Mild to severe
F10 1:500,000 Autosomal recessive (13q34) Mild to severe
F12 Rare Autosomal recessive 5q33 No bleeding
Other contact factors (including
prekallikrein, high molecular
weight kininogen)
Rare, unknown Autosomal recessive (various
genes)
No bleeding
F13 <1:1 million A subunit: 6p24-p25
B subunit: 1q31-q32
Moderate to severe; postoperative
Afibrinogenemia Rare Autosomal dominant (various
mutations at 4q31)
Variable
Dysfibrinogenemia Rare Autosomal dominant (various
mutations at 4q31)
Variable—may be asymptomatic
Hypofibrinogenemia Rare Autosomal dominant (various
mutations at 4q31)
Variable
Combined F5 and F8 Rare Autosomal recessive (18q21, 2p21) Variable
Combined F2, F7, F9, & F10 Rare — Variable
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Box1
Acquired factor deficiencies
Immune-mediated factor deficiencies
Alloantibody factor inhibitors in hereditary hemophilia patients
F8 inhibitors in hemophilia A patients on factor replacement therapy (incidence 5 24% of
hemophilia A patients)
F9 inhibitors in hemophilia B patients on factor replacement therapy (incidence 5 1.5–3%
of hemophilia B patients)
Autoantibodies causing acquired hemophilia
Acquired hemophilia A (most common, may cause severe bleeding)
Prothrombin deficiency complicating the antiphospholipid syndrome (rare)
Acquired F5 deficiency (from antibodies to bovine thrombin preparation used in certain
fibrin glues, uncommon)
Nonimmune-mediated
Increased destruction
Disseminated intravascular coagulation (DIC)
Extracorporeal membrane oxygenation (ECMO)
Fibrinolytic drugs in thrombolytic therapy (eg, tissue plasminogen activator)
Decreased production
Liver disease
Abnormal production
Warfarin use
Other causes of vitamin K deficiency
Loss and sequestration
Nephrotic syndrome
Acquired F10 deficiency associated with light chain amyloidosis (accelerated removal of
F10 caused by adsorption of the factor to the amyloid fibrils); 8.7% of amyloidosis patients
had F10 levels less than 50% of normal; 56% of these had bleeding complications if F10
less 25% of normal; can be fatal
Plasma exchange apheresis (particularly decreased fibrinogen)
Inactivation
Direct thrombin inhibitor use (eg, hirudin, argatroban)
Wagenman et al4
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ARTICLE IN PRESSpatients may not have a family history. Activity assays sometimes are performed on
cord blood from male newborns delivered to a known carrier in a family with severe
hemophilia. This is of particular interest in premature infants, as there is increased
risk of intracranial bleeding.5 It is an important caveat that such results must be inter-
preted with caution, as cord blood is not an optimal specimen for coagulation testing.
This is because activation of clotting in cord blood often occurs during the delivery and
subsequent blood collection processes, and cord blood samples are clotted
commonly, at least partially. In addition, maturation of the hemostatic system occurs
during childhood, such that newborns generally have lower levels of some factors thanCLL469_proof  13 June 2009  2:22 pm
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ARTICLE IN PRESSadults. For example, the mean F9 in newborns has been reported at only 53% for full-
term and 35% for healthy premature infants, with F11 at 38% and 30%, respectively.
Exceptions to this maturation are F8 and vWF levels, which are typically greater than
or equal to100% in both full-term and healthy premature infants.6 Testing of boys from
families that have milder forms of the disease typically can be performed later in child-
hood, preferably before they begin learning to walk.
The clinical manifestations of hemophilia A usually correlate with the severity of the
deficiency measured in the laboratory. Because the difference between severe (less
than 1% F8 activity) and moderate hemophilia (1 to 5%) is clinically significant, labo-
ratory assays should have linearity down to less than 1%. In recent decades, there has
been dramatic improvement in long-term treatment using both plasma-derived factor
concentrates and recombinant factors. Today, because of prophylactic regimens and
early treatment of bleeding episodes, many young adult males who have severe
hemophilia A do not exhibit some of the classical clinical manifestations that include
joint arthropathy from repeated bleeding into joints, contractures of musculature
from frequent muscle and joint involvement, hemorrhage from mild trauma, and
even central nervous system (CNS) bleeds.
Severe cases often receive prophylactic factor administration, either primary
prophylaxis, before development of any joint bleeding (a hallmark of hemophilia), or
secondary prophylaxis, after a significant bleed into a vital organ, or after development
of a target joint. The US Centers for Disease Control and Prevention definition of
a target joint is that a minimum of four bleeds must have occurred in that joint within
a consecutive 6-month period. Cryoprecipitate and fresh-frozen plasma revolution-
ized the treatment of hemophilia A about 50 years ago. The ease of use and safety
of purified factor concentrates and their recombinant counterparts, however, have
replaced these blood products for hemophilia therapy in industrialized nations. Cryo-
precipitate and plasma, however, remain the mainstays of treatment for bleeding in
economically challenged countries around the world.
Infusion of factor at home has also revolutionized management of these patients.
Home treatment allows for early institution of replacement products at the first sign
of a bleed, which decreases the morbidity of these bleeds significantly. In patients
who have mild deficiency, DDAVP can be used as an alternative to factor, either intra-
venously or by nasal spray. DDAVP increases both F8 and vWF and thus aids hemo-
stasis in those hemophiliacs who are mildly affected. However, before its use, each
patient should be evaluated for their response to DDAVP. In addition, antifibrinolytic
agents can be used as adjunct therapies, especially for mucosal bleeding.
Female carriers of hemophilia typically have low-normal to moderately decreased
factor levels, but have been reported as low as 5%. As many as 10% of carriers will
have levels less than 30%. Some carriers, therefore, may have a mild-to-severe
bleeding phenotype, particularly with major hemostatic challenges such as surgery,
and their factor levels will need to be monitored for such procedures.
In addition to using factor activity assays to diagnose deficiency, a significant part of
the coagulation laboratory workload is to monitor hemophilia treatment and to screen
for increased clearance of administered factor caused by possible inhibitor formation.
Factor 9 Deficiency (Hemophilia B)
Sometimes known as Christmas disease (after the surname of the first patient diag-
nosed with this disorder), hemophilia B is caused by a deficiency of F9, an enzyme
rather than a cofactor, which activates F10. Hemophilia B is analogous to hemophilia
A in many aspects. It is only about one-fifth as common, but follows similar clinical
patterns in disease manifestation and severity. Although also X-linked, hemophilia BCLL469_proof  13 June 2009  2:22 pm
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ARTICLE IN PRESSshows tremendous heterogeneity at the molecular level, making genetic screening
much more difficult. The F9 mutation unique to each family needs to be identified
before prenatal or other genetic screening can be performed.
Cryoprecipitate does not contain significant amounts of F9 and therefore cannot be
used to treat this disease. Prothrombin complex concentrates once were used to treat
the disease before specific factor products became available (both plasma-based and
recombinant). It is important to note that some patients who have hemophilia B will
develop allergic reactions to the infusion of these factors, including anaphylaxis.
Hence, the first 10 to 15 infusions usually are administered in a clinic or hospital
setting. As in hemophilia A, home therapy is an effective strategy in reducing the
morbidity of bleeding in these patients. Patients who have mild hemophilia B may
have normal or near-normal aPTT results. Therefore, specific factor assays should
be performed in working up undiagnosed mild bleeding disorders, even if the aPTT
is within the normal range.
Factor 11 Deficiency
In contrast to hemophilias A and B, F11 deficiency (which used to be termed hemo-
philia C)7,8 is an autosomal disorder with variable penetrance. The gene is located
on chromosome 4 (4q35.2). In addition, the bleeding manifestations are heteroge-
neous in relation to the factor activity levels (ie, there is a poor correlation between
bleeding manifestations and the baseline F11 clotting activity, unlike hemophilia A
and B). Thus, separation of patients into distinct clinical phenotypes is less clear-
cut than in other bleeding disorders. Many patients do not exhibit bleeding until chal-
lenged with trauma or surgery; unlike hemophilia A and B, bleeding in F11 deficiency is
often mucosal. Patients who have severe deficiency (levels less than 15% to 20%)
have a high probability of postoperative bleeding. This, however, is not a uniform
finding, and some may not bleed at all. Yet, patients who have mild deficiency may
have severe bleeding when hemostatically challenged (eg, by platelet-inhibitory
drugs). The reason for this discrepancy is unclear, but one possible explanation
may be the coexistence of other bleeding disorders like vWD, which could contribute
to the bleeding risk in thesemildly deficient patients. Hence, it is important from a labo-
ratory standpoint to consider testing for coinheritance of other bleeding disorders.
Because many of these patients are asymptomatic until challenged by surgery or
trauma, the diagnosis often is made in late childhood or early adulthood. Over half
of the cases are diagnosed in patients of Ashkenazi Jewish descent. In this group, it
is estimated that one in eight individuals are heterozygous for a gene defect, and 1
in 190 are homozygous.
Generally, screening coagulation tests will reveal an isolated prolonged aPTT with
F11 deficiency. Because different partial thromboplastin reagents vary in sensitivity
to F11, reference ranges should be established in each local laboratory. F11 assays
should be performed based on clinical suspicion. Most identified mutations cause
type 1 deficiency, with reduced amounts of normal F11 antigen leading to a lower
concentration of the protein in the plasma. Because F11 antigen measurements corre-
late with activity levels, determination of antigen levels is not recommended routinely
as part of the testing process. Given the poor correlation of F11 activity levels and
bleeding risk, researchers are looking into global tests of hemostasis (thrombin gener-
ation, thromboelastography) to understand the role of F11 in hemostasis (see article
by Teruya in this issue). Specific F11 replacement concentrates are available in the
European Union and experimentally in the United States. Fresh-frozen plasma
remains the mainstay of treatment in the United States, along with adjunct therapies
like antifibrinolytic agents.CLL469_proof  13 June 2009  2:22 pm
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ARTICLE IN PRESSOther Inherited Factor Deficiencies
Genetic mutations may occur in any of the proteins involved in the formation of the
fibrin clot or in regulation of the coagulation pathways. Deficiencies of some of these,
such as tissue factor, do not appear to be compatible with life. Mutations of factors
other than 8, 9, and 11 are typically very rare, and these are especially heterogeneous
with respect to the range of bleeding symptoms (from none to severe).9
Deficiencies of factor 12 and other contact factors
Deficiencies of factors in the contact pathway of coagulation are typically autosomal
recessive and include F12, prekallikrein (Fletcher factor), and high molecular weight
kininogen. These coagulation curiosities produce a markedly prolonged aPTT in the
test tube, but cause no bleeding diatheses. This is likely because the contact factors
lack amajor role in the in vivo clotting process (see article by Kriz and colleagues, else-
where in this issue). F12 deficiency is the most common cause of an isolated and
significantly prolonged aPTT in a nonbleeding patient, after ruling out heparin contam-
ination and lupus anticoagulant (LA). Severe F12 deficiency is rare, and patients may
never be identified unless an aPTT is performed for another indication. Although there
are few if any clinical consequences, the patient, laboratory, and clinical care team
should be aware of the situation so that unnecessary concern is avoided in the future
if an aPTT is ordered again by an unknowing caregiver. Deficiencies of the other
contact factors are much less common, and confirmation of these deficiencies may
be performed by reference coagulation laboratories.
Deficiencies of factors 2 (prothrombin), 5, 7, and 10
In contrast to contact factor deficiencies, decreased activity of factors 2, 5, 7, and 10
often lead to bleeding disorders of varying severity.10–14 These are all very infrequent,
autosomal recessive disorders (incidence of less than 1 in 500,000).
Prothrombin deficiency is not always severe, because there is normally a large
molar excess of F2 over the minimum needed to prevent bleeding. Bleeding is seen
predominantly in homozygous or compound heterozygous individuals, and can be
moderate to severe. In the laboratory, prothrombin deficiency is characterized by
both a prolonged PT and aPTT. If clinical suspicion warrants, an F2 activity assay
should be performed. Activity testing most often is performed using a one-stage
assay. The prothrombin gene is found on chromosome 11p11.2. More than 40
different mutations have been identified in this deficiency. Given the rarity of this
disorder, a clear genotype/phenotype correlation is difficult to ascertain, but the lower
the levels, the greater the severity of bleeding; symptoms include mucosal bleeding,
surgical and trauma related hemorrhage, hemarthroses, and intracranial bleeding.
Treatment of bleeding episodes usually is accomplished by use of plasma or pro-
thrombin complex concentrate (PCC), which contains F2, F7, F9, and F10. The exact
amount of F2 in these products is unknown. PCC usually is dosed based on the F9
units in each lot. Hence, the dose of PCC will vary from product to product and
may lead to supratherapeutic levels of the other transfused factors; this may increase
the risk of thrombosis. Thus, PCC dosing is limited to less than 200 U/kg/d. Monitoring
of this therapy is done by following the PT/aPTT or by specific F2 assays.
Theclinical variability of F5deficiency is complicatedby the fact that F5 is foundwithin
platelet alpha-granules and inplasma.Aside frommutations that give rise to inheritedF5
deficiency, deficiencies of F5 also can be acquired secondary to F5 inhibitors that result
from exposure to bovine thrombin. Activated F5 serves as a cofactor in the prothrombi-
nase complex (like F8 in the tenase complex) that cleaves andactivates F2. Like F11, the
F5 activity level has limited correlation with the severity of bleeding, but the lower theCLL469_proof  13 June 2009  2:22 pm
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ARTICLE IN PRESSlevel, the greater the severity of bleeding. Patients who are seen clinically for bleeding
usually have levels less than 5%. Data from the bleeding registries suggest that these
patients usuallypresentwith skin andmucosal bleedings, but themoreseverelyaffected
maypresentwithCNSbleeds, hemarthrosis, ormuscular bleeds,which explainswhyF5
deficiency hasbeen termedparahemophilia. Thegene for F5 is locatedon chromosome
1q23. More than 60 mutations associated with F5 deficiency have been identified.
Similar to F2 deficiency, F5 deficiency is characterized by prolongation of both the PT
and aPTT. If a low F5 is found, then inherited F5 deficiency must be distinguished
from DIC, liver disease, combined deficiencies, or an acquired inhibitor. Plasma is the
mainstay of therapy in these patients; however, platelet transfusions also may be
beneficial in resistant bleeding cases and for outpatient therapy.
F7 deficiency is the most frequent among the more rare congenital bleeding disor-
ders, characterized by an isolated prolongation of the PT. The gene is located on the
long arm of chromosome 13. To date, more than 130 mutations have been reported.
Similar to other rare bleeding disorders, bleeding in these patients is heterogeneous
both in regards to site and severity, and the correlation between circulating F7 and
clinical bleeding is not linear. Patients who present early in life (younger than 6 months)
or have CNS or gastrointestinal (GI) hemorrhage or hemarthrosis, however, are clearly
considered to be severe cases. The F7-dependent PT clotting assay is easily avail-
able, but nuances in the influence of different thromboplastin reagents on the specific
assay must be considered. For example, if the PT with a purified thromboplastin
reagent is prolonged in an African American patient (especially without a history of
clinical bleeding), a F7 polymorphism may be present that actually yields a normal
PT result using recombinant human thromboplastin. Several F7 plasma-derived prod-
ucts are available in the European Union to treat severe bleeding cases, but therapy is
complicated by the short in vivo half-life of F7, especially in children who are the most
severely affected. Hence, these products have to administered frequently. In addition
to plasma-derived F7 products, the recombinant form of activated F7 is also available
(NovoSeven, Novo Nordisk, Bagsvaerd, Denmark) worldwide.
F10 is a liver-produced serine protease that serves apivotal role as the first enzyme in
the common pathway of clot formation. Patients who have severe deficiency tend to
have the most severe symptoms, and patients are classified similar to hemophilia as
severe (less than 1% of F10 clotting activity), moderate (1% to 5%), and mild (6% to
10%). Severe F10 deficiency is one of the most rare disorders. The gene for F10 is
located on chromosome 13q34-ter. More than 80 different mutations have been iden-
tified thus far. In contrast to F8 and F9 deficiency, the most frequent bleeding manifes-
tationsaremucocutaneous, including severemenorrhagia.Hemarthrosis alsohasbeen
reported in rare patients. Patients who have severe deficiency may present in the
newborn period with bleeding after circumcision, from the umbilical stump, or with GI
or CNS hemorrhage. The diagnosis should be suspected when both the PT and aPTT
are prolonged; the F10 functional assay will reveal the deficiency. Like F11, F10 levels
are lower at birth, and do not approximate adult values till after 6 months of age. F10
replacement therapy is achieved with plasma or PCC (dosing is again by F9 units).
Deficiencies of factors 1 (fibrinogen) and 13
Fibrinogen (F1) is neither a cofactor nor an enzyme, but a glycoprotein produced in the
liver that serves as a substrate tomake fibrin clots.Unlike factor assays,whichgenerally
are reported as activity, the laboratory typically reports fibrinogen concentration, rather
than activity. Prothrombin (F2) cleaves two small fibrinopeptides from fibrinogen, allow-
ing it to spontaneously aggregate. In normal physiology, these cleavage products poly-
merize noncovalently to forma fibrin clot that subsequently is cross-linkedcovalently byCLL469_proof  13 June 2009  2:22 pm
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ARTICLE IN PRESSF13. It is one of these covalent bonds between theD regions of two fibrinmolecules that
produces the D-dimers measured in the laboratory after degradation of the clot during
fibrinolysis. Fibrinogen contains many specific binding sites and plays other adhesive
roles in addition to that of a substrate in secondary hemostasis. Fibrinogen interacts
with platelet GPIIb-IIIa, fibronectin, and collagen in cell-based hemostasis. Inherited
disorders can manifest as quantitative defects (afibrinogenemia/hypofibrinogenemia)
or qualitative defects (dysfibrinogenemia), and clinicalmanifestations vary fromasymp-
tomatic to life-threatening bleeds, and paradoxically even to thromboembolic events.
Afibrinogenemia often is diagnosed in the newborn period with umbilical cord
bleeding or other severe life- or limb-threatening bleeding. Hypofibrinogenemia pres-
ents with lesser bleeding episodes and usually is diagnosed after a challenge to the
hemostatic system, while dysfibrinogenemia is diagnosed commonly during adult-
hood and also may be acquired with liver disease. In afibrinogenemia, all coagulation
tests that depend on fibrin as the endpoint (PT, aPTT, thrombin time, reptilase time)
are prolonged infinitely, and fibrinogen is undetectable by both functional (von Clauss)
and antigenic assays. A fibrinogen level less than 100 mg/dL often will translate to pro-
longed PT and aPTT. In hypofibrinogenemia, the thrombin time is a very sensitive test,
and is confirmed by an abnormal reptilase time. In dysfibrinogenemia, there is usually
a discrepancy between clottable protein and antigenically measured fibrinogen.
Replacement therapy is generally effective in treating bleeding episodes caused by
any of the fibrinogen disorders, including cryoprecipitate and plasma-derived fibrin-
ogen concentrate (RiaSTAP, CSL Behring, King of Prussia, PA, recently approved
by the US Food and Drug Administration).
Inherited dysfibrinogenemia is an autosomal-dominant type 2 defect, with several
identified mutations. The thrombin and reptilase times are prolonged. The former is as-
sayed after the addition of thrombin to patient plasma, directly converting fibrinogen to
fibrin. The thrombin time is sensitive to any deficiency of functional fibrinogen but is
also very sensitive to heparin, which greatly increases the inhibition of added thrombin
by endogenous antithrombin. The reptilase time is also sensitive to fibrinogen defi-
ciencies. Reptilase is a thrombin-like molecule derived from snake venom that directly
cleaves fibrinogen and allows clot formation, but is not affected by heparin, as repti-
lase is not inhibited by antithrombin.
Deficiency of F1315 leads to an unstable clot that may be dissolved or dislodged
by trauma. The short life of the uncross-linked clot leads to symptoms of delayed
bleeding, often presenting as late umbilical cord bleeding (and poor wound healing).
A specific F13 activity level is performed by some reference laboratories, but the
most common test used to screen for homozygous (severe) F13 deficiency is urea
clot lysis. Urea is a chaotropic agent that enhances the dissociation of the uncross-
linked fibrin molecules in patients who have severe F13 deficiency. This test involves
clotting the plasma, adding 5 mol/L urea, then assessing the time to clot dissolution.
The thromboelastograph also can be used to diagnose F13 deficiency as evidenced
by reduced maximal amplitude and a rapid decrease in clot size and strength (see
article by Teruya in this issue). Plasma F13 is a heterotetramer (FXIII-A2B2). The
gene coding for FXIII-A subunit is on chromosome 6p24-25, while that for the FXIII-
B subunit is on chromosome 1q31-32.1. Congenital deficiency can be caused by
defects in either FXIII-A (type 2 defect), usually resulting in clinical bleeding, or FXIII-
B (type 1 defect), where bleeding occurs infrequently. More than 70 subunit gene
mutations have been identified (67 in subunit A, only 4 thus far in subunit B). In those
homozygous patients with levels that are either absent or less than 5% (variability
caused by assay inaccuracy), F13 deficiency is associated with severe bleeding, spon-
taneous intracranial hemorrhages, poor wound healing, and spontaneous abortions.CLL469_proof  13 June 2009  2:22 pm
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ARTICLE IN PRESSHeterozygotes are usually asymptomatic. Replacement therapy includes cryoprecipi-
tate and a plasma-derived FXIII concentrate (Fibrogammin, ZLB Behring, Marburg,
Germany) approved in the European Union, but also available on a compassionate
basis in the United States at the time of this writing.
Combined factor deficiencies
Many rare combined factor deficiencies have been identified in various pedigrees (see
Table 1 for examples). In the laboratory, if a single factor deficiency is diagnosed but
does not explain all of the abnormal screening tests, the presence of an additional
deficiency should be considered. Combined deficiency of both F5 and F8 can result
from mutations in either the LMAN1 (located on chromosome 18q21) or MCFD2
(located on chromosome 2p21) genes encoding proteins that shuttle these factors
from the endoplasmic reticulum to the Golgi complex. The deficiency is characterized
by concomitant low levels (usually 5% to 20%) of both F5 and F8, and it is associated
with mild-to-moderate bleeding. Treatment requires both F5 and F8 replacement.
Combined deficiency of F7 and F10 has been reported with 13q deletions; the two
genes are located very close to each other. Combined deficiencies of the vitamin
K-dependent proteins 2, 7, 9, 10 can occur when there is an abnormality in the
gamma–glutamyl carboxylase gene or the vitamin K epoxide reductase complex.
ACQUIRED FACTOR DEFICIENCIES
In contrast to the rare inherited deficiencies, coagulation factor deficiencies are
acquired commonly.16 These include deficiencies secondary to autoantibody forma-
tion leading to neutralization of factor activity or rarely, accelerated clearance from
the circulation.17 Other acquired causes include decreased production (eg, liver
disease), impaired synthesis (eg, vitamin K deficiency), and increased destruction
(disseminated intravascular coagulation and thrombolytic therapy).
Immune-mediated Acquired Factor Deficiencies
A complex interaction of several variables leads to inhibitor formation in congenital
hemophilia, while acquired hemophilia in genetically normal individuals represents
a failure of immune tolerance mechanisms.18 The development of inhibitor antibodies
is perhaps the most serious complication of coagulation factor replacement therapy in
congenital hemophilia, while acquired hemophilia represents an uncommon disorder
in older adults that is generally responsive to current immunosuppressive regimens.
Alloantibody factor inhibitors in hereditary hemophilia
Inhibitors of congenital hemophilia are alloantibodies stimulated by infusion of exog-
enous factor that contains epitopes that may not be present on the mutated endoge-
nous factor.3,17,19 These antibodies complicate the treatment of bleeding, because
they bind and inactivate infused factor, or occasionally accelerate its clearance, often
rendering standard factor replacement therapy ineffective. Approximately 20 to 30%
of severe hemophilia A patients develop inhibitors, and this incidence is even higher in
children who have large deletions or inversions. Inhibitors are far less common in
moderate and mild hemophilia A and in severe hemophilia B (less than 5% in the
latter). Inhibitors cause management of these patients to become more difficult and
costly. The antibodies not only neutralize the infused factor but also may cross-react
with endogenous factor, sometimes resulting in the conversion of moderate hemo-
philia to a severe phenotype.
Coagulation laboratories supporting hemophilia centers typically quantitate the titer
of inhibitor (Bethesda units (BU)/mL) present using a series of F8 assays that haveCLL469_proof  13 June 2009  2:22 pm
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ARTICLE IN PRESSbeen modified to show neutralization of human F8 (Fig. 1). In patients who have high
inhibitor levels (greater than 5 BU/mL) and severe bleeding, therapies to bypass the
defect in the coagulation cascade must be used, because the antibody simply neutral-
izes the large amounts of factor that are infused. Recombinant activated F7 (rVIIa,
Novoseven) and activated prothrombin complex concentrates (FEIBA, Baxter Health-
care, Westlake Village, CA, USA) are the most commonly used bypass drugs.20 These
agents directly stimulate F10 activation without involvement of the missing intermedi-
aries (F8 or F9). The coagulation laboratory should be informed if bypass agents have
been administered before any coagulation testing, as these may alter the results and
clinical interpretation dramatically.
Autoantibodies causing acquired hemophilia
The laboratory diagnosis of acquired hemophilia typically is made when an isolated
factor deficiency is identified in a patient with clinically significant bleeding who hasFig.1. To quantitate a factor 8 (F8) inhibitor, patient plasma is incubated with a source of F8
(normal pooled plasma) at 37C for 2 hours. A control (F8 deficient plasma 1 normal pooled
plasma) is also incubated at 37C for 2 hours. Residual F8 activity is then measured on both
mixtures. The residual F8 activity of the patient mixture is compared to that of the control
mixture (patient/control). If the resulting ratio is <0.40, the patient sample will need to be
diluted in either buffer (Bethesda assay) or F8 deficient plasma (Nijmegen modification).
The reciprocal dilution of patient plasma that results in a F8 activity that is 50% of that
of the control mixture is defined as one Bethesda unit (BU). The stronger the inhibitor,
the greater the dilution required to allow for expression of the F8 activity. In this example,
after incubation, the patient’s sample had a residual F8 activity of 25% compared to the
50% seen in the control (ratio of patient/control 5 0.50). This patient has a 1 BU inhibitor.
If the ratio of patient to control is >80%, this suggests no inhibitor (or a clinically insignif-
icant inhibitor).
CLL469_proof  13 June 2009  2:22 pm
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ARTICLE IN PRESSa negative personal and family history of a bleeding disorder. The most common enti-
ties caused by autoantibodies to coagulation factors are acquired hemophilia A,21,22
followed by prothrombin deficiency complicating the antiphospholipid syndrome,
and acquired F5 deficiency after surgical use of bovine thrombin. These coagulation
factor deficiencies are uncommon acquired conditions that can lead to serious hemor-
rhage. Acquired hemophilia A typically presents in older patients who have no prior
history of a bleeding disorder; about one-third of these patients will
have underlying disorders (autoimmune diseases such as systemic lupus erythe-
matosus or rheumatoid arthritis), have lymphoproliferative disorders such as
chronic lymphocytic leukemia,
be peripartum, or have been treated with drugs such as penicillin and
sulfonamides.
Whereas inhibitors that occur with inherited hemophilia A may be treated with heavy
immunosuppressive therapy, autoantibodies that develop in patients who have
acquired hemophilia A often respond to a single course of therapy (eg, anti-CD20
[rituximab]).22
Other acquired inhibitors include prothrombin deficiency, which typically occurs
with persistent lupus anticoagulants, and, unlike the underlying procoagulant disorder,
F2 deficiency is associated with bleeding that is responsive to plasma or PCC therapy.
Rare autoantibodies against F5 or F13 also can cause bleeding.
The development of alloantibodies against bovine F5 that contaminate thrombin
preparations used in certain fibrin glues is documented.11,23 This inhibitor is in addition
to antibodies toward the bovine thrombin itself. Antibodies to bovine F2 generally only
create in vitro laboratory excitement by significantly prolonging assays using bovine
thrombin as a reagent. Conversely, the antibodies against bovine F5 can cross-react
with human F5, creating serious acquired bleeding disorders. Recent preparations of
fibrin glue and use of recombinant thrombin (eg, Recothrom, ZymoGenetics, Seattle,
WA, USA) may lower the risk of developing these antibodies.
Nonimmune-mediated Acquired Factor Deficiencies
Acquired nonimmune causes of factor deficiencies often are detected in the coagula-
tion laboratory. These include the following:
Increased destruction. Coagulation factors—particularly fibrinogen— may be
depleted by rapid factor activation and eventual consumption in conditions
such as DIC. Clinical interventions such as artificial heart valves, left ventricular
assist devices, and ECMO also may lead to factor depletion in varying degrees.
The administration of fibrinolytic drugs in thrombolytic therapy (eg, tissue plas-
minogen activator) also decreases some factor levels.
Decreased production. Conditions that lead to decreased production of coagula-
tion factors are seen commonly in the hospital laboratory. A common example
of this is liver disease (see article by Ng in this issue).
Abnormal production. In addition to decreased production, abnormal production of
coagulation proteins also is seen in liver disease. Posttranslational modification
of fibrinogen, which is detrimental to its function (dysfibrinogenemia), occurs in
patients who have liver disease, and also may be seen in the fetus or newborn.
Yet, the prime example of abnormal coagulation factor production is iatrogenic
and caused by warfarin (Coumadin) therapy. Warfarin removes the ability of the
vitamin K-dependent factors (2, 7, 9, 10, and proteins C and S) to bind to the
surfaces where coagulation reactions occur. Warfarin acts by interfering withCLL469_proof  13 June 2009  2:22 pm
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ARTICLE IN PRESSthe vitamin K-dependent gamma carboxylation of these particular factors, re-
sulting in the formation of protein induced by vitamin K absence or antagonists
(PIVKA). These modified factors are unable to bind calcium and therefore cannot
be anchored to the phospholipid membrane (see article by Ng in this issue). As
the proteins cannot bind to the areas of active clotting, the effective concentra-
tions are decreased greatly.
Loss and sequestration. Proteins lost in conditions like nephrotic syndrome include
some involved in hemostasis regulation, such as antithrombin. Acquired F10
deficiency is rare; it usually is associated with light chain amyloidosis as a result
of accelerated removal of F10 by adsorption onto the amyloid fibrils.24 An iatro-
genic source of factor loss is plasmapheresis, which will lower the coagulation
factors by straightforward plasma removal, unless the treatment indication
requires plasma replacement (plasma exchange). If plasma is not used as
a replacement fluid, fibrinogen (F1) deficiency commonly will limit the frequency
of exchanges.
Inactivation. It must not be overlooked that many pharmacologic inhibitors to coag-
ulation factors are entering the clinical arena rapidly. These include the direct
thrombin inhibitors (DTI) such as hirudin and argatroban. As might be imagined,
inhibition of one of the key factors in the coagulation cascade wreaks havoc
upon all of the clot-based assays used in the coagulation laboratory. It is critical
that the laboratory be informed when such agents are in therapeutic use to have
a reasonable interpretation of coagulation results, including factor assays. A
normal thrombin time result is useful in ruling out an effect of DTI.THE LABORATORY EVALUATION OF FACTOR DEFICIENCY
Preanalytical Considerations
Any coagulation assay is only as good as the sample submitted. Although preanalyt-
ical variables can affect any laboratory test, coagulation testing is particularly influ-
enced by collection and handling processes.25 Inaccurate results caused by
improper collection or handling may lead to inappropriate patient intervention and/
or additional unnecessary testing. To ensure a quality sample, one must adhere to
the current Clinical and Laboratory Standards Institute (CLSI) guidelines for collecting
and handling light blue top tubes (H21-A5).26 Box 2 outlines a checklist of key prea-
nalytical considerations.
The proper anticoagulant is 3.2% (109 mmol/L) buffered trisodium citrate (light blue
top tubes). This blue-top tube is required for most coagulation tests performed by the
laboratory. The citrate anticoagulant chelates calcium, thus preventing the sample
from clotting. For accurate results, a blood-to-anticoagulant ratio of 9:1 must be main-
tained. If the patient has a hematocrit of greater than 55% and thus a significantly
reduced plasma volume, the amount of citrate must be reduced similarly to prevent
falsely prolonged clotting times because of a relative excess of citrate. Too little citrate
(as seen when the hematocrit is less than 20%) may not prevent factor activation or
clotting in the tube. For this reason, it is recommended that patient samples should
be checked for a clot whenever clotting times are inexplicably longer or shorter
than either the reference or therapeutic range.
If the sample is collected using a winged blood collection set (ie, butterfly) and
a vacuum tube, a discard tube should be drawn first to prevent underfilling of the
tube because of the extra air within the collection set. Drawing a discard tube first
is also advisable when drawing samples for any coagulation assay beyond routine
PT and aPTT testing, although there are no current studies proving this is necessary.CLL469_proof  13 June 2009  2:22 pm
Box 2
Preanalytical checklist.These questions should be asked as part of the preanalytical checklist
to determine sample integrity
Was the specimen collected in the correct anticoagulant?
Are the tubes properly filled?
Was the sample collected through a venous access device?
Is the hematocrit less than 55%?
Is the sample already clotted?
Is the plasma platelet-poor?
Is the sample hemolyzed?
Is the sample lipemic or icteric?
Has the sample been maintained either at room temperature or frozen?
Has the sample age exceeded the stability limit?
Wagenman et al14
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ARTICLE IN PRESSWithin 4 hours of collection, (1 hour for assays evaluating heparin), the blood must
be centrifuged and plasma processed for testing or freezing. A two-spin centrifugation
method will ensure that the resulting plasma is truly platelet-poor, because phospho-
lipid from residual platelets interferes with many coagulation assays. Plasma should
be kept at room temperature until testing or freezing, because both vWF and F8
activity can be lost with 4C storage. Frozen plasma must be stored at -20C or lower
(preferably -70C), and avoiding the use of a frost-free freezer, as the periodic defrost
cycles allow samples to partially thaw and then refreeze. Frozen plasma should be
thawed at 37C just before testing, avoiding any refreezing of plasma, as the coagu-
lation proteins tend to denature with more than one freeze–thaw cycle.
Using the Prothrombin Time and Activated Partial Thromboplastin Time to Screen
for Factor Deficiency
Establishing reference ranges
To successfully use the PT and aPTT as screening tests, the coagulation technologist
needs to be very familiar with the characteristics of the reagent/instrument systems.
Selecting a combination of coagulation reagents and analyzers that facilitate the iden-
tification of patients with factor deficiencies or inhibitors is critical. The aPTT reagents
touting lupus anticoagulant sensitivity should be reserved for actual LA testing. For PT
testing, it is preferable to use a low International Sensitivity Index (ISI) reagent contain-
ing a heparin neutralizer; the latter enables accurate PT results in patients who are
receiving both warfarin and heparin. The neutralizer generally is effective when heparin
levels are less than or equal to 1 U/mL, but can be overwhelmed by contaminant
heparin when specimens are drawn from an indwelling line.
To establish a valid reference range for the PT and aPTT, a pool of normal subjects
must be identified. These subjects should match the patient population as closely as
possible. This may be difficult if the population includes pediatric patients. In the
absence of a neonatal or pediatric pool of donors, onemust rely on published reference
ranges for children of various ages.6,27 Adult outpatients canbeused to establish ranges
as longas theydonothaveorders forcoagulation assays (suspectedbleedingor clotting
history) and additionally meet predefined criteria (Box 3). Historically, donors who were
onoralcontraceptives (OCPs)wereexcluded fromthenormaldonorpool, butmanysites
now include them,because they constitute a largeportion of thepopulation to be tested,CLL469_proof  13 June 2009  2:22 pm
Box 3
List of donor requirements for use as normal donor plasma. Criteria for inclusion in a normal reference
range study
Not pregnant
Not taking anticoagulants
Not taking antibiotics
Not taking insulin
No history of a blood clot
No history of a bleeding disorder
No history of autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis)
Coagulation Factor Deficiencies 15
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ARTICLE IN PRESSand newer OCPs contain less estrogen. Estrogen may increase ambient F8 and vWF
levels, thus shortening the aPTT in affected patients. This is illustrated from data
collected from students at the authors’ institution, where the average aPTT of women
using OCP was 27.6 seconds, n518, while for women not on OCP, the average aPTT
was 29.5 seconds, n514, (P5.026). For men the average was 29.4 seconds, n518.
Ideally, donor samples should be collected and tested over a period of days or
weeks. They should be centrifuged and analyzed in the same manner as patient
samples. A bare minimum of 20 donors (10 male and 10 female) can be used to verify
the reference range of a new lot of a current reagent; however, when changing type of
reagent, at least 50 donors should be used. Statistical analysis also will determine the
required geometric mean PT value for international normalized ratio (INR) calculation.
In order to interpret results of the PT and aPTT, it is helpful to know their sensitivity
for factor deficiencies. To evaluate a reagent for factor sensitivity, one may dilute
a pooled normal plasma into factor-deficient plasma to achieve factor activities of
60%, 50%, 40%, 30%, and 20%. The appropriate factor assay then is performed,
as well as a standard PT and aPTT on each dilution (Fig. 2). The percent activity is
plotted against the clotting time in seconds to determine what clotting time corre-
sponds to a factor activity level of 30%, which generally is considered to be the
minimum amount of factor activity needed for consistent hemostasis (Table 2).aPTT Sensitivity to Factor 8 Deficiency
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Factor 8 Sensitivity = 32.5%
Normal Plasma Dilutions with
F8 Deficient Plasma
Fig. 2. Determining the upper limit of the activated partial thromboplastin time (aPTT) refer-
ence range is aided by measuring the factor 8 activity against the aPTT. Using dilutions of
control plasma, a factor 8 activity of approximately 32.5% confirms the statistically-derived
upper limit of normal of 37.0 seconds.
CLL469_proof  13 June 2009  2:22 pm
Table 2
Half-lives and hemostatic levels of coagulation factors
Factor Category Approximate Half-Life Approximate Hemostatic Level
Fibrinogen Substrate 96 hours 50 mg/dL
F2 Protease 72 hours 20%
F5 Cofactor 16 hours 25%
F7 Protease 4 hours 20%
F8 Cofactor 11 hours 30%
F9 Protease 22 hours 30%
F10 Protease 30 hours 25%
F11 Protease 60 hours 25%
F13 Transglutaminase 10 days 2% to 3%
Some table content courtesy of George Fritsma (www.fritsmafactor.com).
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ARTICLE IN PRESSThe reference ranges for both PT and aPTT should be established for each lot of
reagent by examining both the statistical analyses and the results of the factor sensi-
tivity studies. The upper and lower limits of normal should initially be set at the 95th
percentile (mean plus or minus 2 SD). The upper limit can then be adjusted so that
true factor deficiencies (less than or equal to 30%) will be detected. If possible, patient
plasmas known to be mildly factor-deficient should be assayed to confirm that the
reference ranges have been set correctly. This procedure is also useful in circum-
stances where the in vitro factor sensitivity curve looks relatively flat in the 30% range
(eg, the F9 curve is relatively insensitive in some reagent systems). Plasma from
patients with mild factor deficiencies should be frozen for future use in setting refer-
ence ranges. The factor sensitivity information should be supplied to hematologists,
pathologists, and all other providers who routinely use the PT or aPTT for screening.Mixing studies
To guide in the evaluation of a prolonged PT or aPTT, mixing studies can be employed
to help discern the presence of factor inhibitors. In its simplest form, one part of patient
plasma is mixed with one part of pooled normal plasma, and the clotting tests are
repeated. Pooled normal plasma supplies the missing factor(s) and corrects the pro-
longed clotting times of patients who have factor deficiency. If a patient has an inhib-
itor (antibody) that interferes with factor activity, the prolonged clotting time should not
correct with addition of normal pooled plasma. A 1- to 2-hour incubation at 37C is
needed for time- or temperature-dependent antibodies to exert their effect. A normal
control must be used for interpretation, as extended incubation may prolong the clot-
ting time of plasma because of factor degradation, without regard to inhibitors or
deficiencies.
Exactly defining a mixing study correction can be difficult, and there are many opin-
ions as to how this should be accomplished.28,29 Some experts suggest that the result
of the mix must correct to within the reference range, while others hold that correction
occurs if the mix result is no greater than 5 seconds above the upper limit of the range.
Others compare the results of the mix with a control of normal pooled plasma. Using
various dilution ratios of patient plasma to pooled normal plasma or incorporating
saline into the mix may increase the sensitivity of the study for an inhibitor.
In practice, in the authors’ laboratories, mixing studies are often misleading.28
Severe factor deficiencies may not correct even though factor levels have beenCLL469_proof  13 June 2009  2:22 pm
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ARTICLE IN PRESSrestored to 50%, depending on where the reference ranges are set in relation to factor
sensitivities. This is especially true with current PT reagents, which are very sensitive;
restoring a factor level to 50% may yield a PT within the reference range. Mixing also
may dilute a mild inhibitor sufficiently, such that clotting times correct. With a good
clinical history and knowledge of one’s laboratory test limits, an experienced coagu-
lation laboratory may be able to determine the cause of a prolonged PT or aPTT
without mixing studies.Factor activity assays
Three types of assays can be used to measure factor activity: chromogenic, one-stage
clotting, and two-stage clotting. Although expensive, chromogenic assays are supe-
rior for measuring factor activity in the presence of LA or heparin, in assigning factor
concentrate potency, and for detecting mild F8 deficiencies that may be missed
with a one-stage clotting assay.
Chromogenic assays are based upon the principle that clotting factors are protein-
ases that specifically cleave their natural substrates. By substituting a chromogenic
substrate that gives off a color when cleaved, the reaction rate and the magnitude
of color development are proportional to the factor activity. Each chromogenic assay
is designed specifically for the factor beingmeasured. For example, onemethod for F8
uses optimal amounts of Ca21, phospholipid, and activated F9, with an excess of F10,
such that the rate of activation of F10 is related linearly to the amount of F8. F10 hydro-
lyzes the chromogenic substrate S-2765, thus liberating a chromophore. The color
then is read photometrically at 405 nm. The intensity of color is proportional to the
amount of S-2765 cleaved by F10 and thus yields the F8 activity in the sample.
Two-stage clotting assays are precise, insensitive to preanalytic factor activation,
and superior at detecting mild F8 deficiency compared with the one-stage assay.
Two-stage assays do not require the use of factor-deficient plasmas, but they are
complicated and not automated easily. For this reason, they are not performed in
many laboratories. In the two-stage method for F8, the patient plasma is treated
with aluminum hydroxide to remove factors 2, 7, 9 and 10. This arrests the clotting
process after formation of the prothrombinase complex. The treated patient’s plasma
then is mixed with activated serum, F5, calcium, and phospholipids to initiate coagu-
lation and generate activated F10. After a defined period of incubation, one volume of
this mixture is added to one volume of normal plasma, and the time to clot formation is
measured. Clotting times of a calibrator or standard plasma are plotted, and the F8
level in the patient sample is read from the graph.
The one-stage clotting assay is themost commonly usedmethod in clinical laborato-
ries because of its simplicity and automation. Factors 8, 9, 11, and12 typically are tested
usingaone-stageassaybasedon theaPTT.F7 is testedusinganassaybasedon thePT,
while factors 2, 5, and 10 can be assayed using either. The PT-based assay is preferred,
however, because it is faster and less prone to interference by heparin and LA.
Regardless of whether a PT- or aPTT-based assay is used, a calibration curve first
must be prepared. It is important to choose a good calibrator referenced to World
Health Organization standards. The standard curve should be designed to contain
enough points to extend below 1% (especially for factors 8, 9, and 11) so that severe
hemophilia can be differentiated from moderate disease. Some automated coagula-
tion analyzers require the use of a low curve to enhance sensitivity below 20% activity.
The low curve is made by diluting the standard down to approximately 20% before
loading it on the analyzer. The analyzer then can prepare dilutions to include a point
at 1%.CLL469_proof  13 June 2009  2:22 pm
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ARTICLE IN PRESSTo make factor assays more sensitive, patient and calibrator plasma first are diluted
in buffer (longer times are more sensitive to small changes); then the diluted plasma is
mixed 1:1 with factor deficient plasma. An aPTT or PT then is performed on the mix.
Most automated coagulation analyzers prepare all patient and calibrator dilutions
without technologist intervention.
Factor-deficient plasma is provided as a lyophilized powder or frozen plasma. Defi-
cient plasma may originate from a single donor who is congenitally factor-deficient, or
it may be prepared from pooled normal donor plasma by immunodepletion of the
appropriate factor. If an immunodepleted plasma is used, it should be validated to
ensure that only the factor under consideration has been removed. With F8-deficient
plasma, it is important to know if vWF also has been removed, as the absence of vWF
may affect the results of the factor activity assay.
To rule out interference from heparin, LA, or antibodies to another factor, each
sample must be tested at a minimum of three dilutions. If the results, after correcting
for the various dilutions, exhibit increasing activity with each subsequent greater dilu-
tion of the patient plasma, this is termed an inhibitor pattern (Fig. 3). It is important to
note that an inhibitor pattern may not be observed when an antibody is directed
specifically against the factor being tested. Specific factor inhibitors usually bind to
the factor and completely interfere with its coagulation function, preventing it from
being measured in an activity assay. Subsequent dilutions do not produce a rise in
factor activity.
Heparin causes aPTT-based assays to have prolonged clotting times (and thus
falsely low factor activity). When the patient plasma is diluted out, the heparin also
is diluted, causing less interference in the assay and resulting in an apparent increase
in factor activity. A prolonged thrombin time with a normal reptilase time (or measuring
the actual heparin level) will confirm heparin as the cause of an inhibitor pattern.
LA may show an inhibitor pattern in a manner similar to heparin. The antibody inter-
feres with phospholipid in the PT- or, most often, acPTT-based assays and leads to
prolonged clotting times. As the patient plasma is diluted, the antibody also is diluted,
causing less interference and thus higher—and more accurate—factor activity withNonlinearity of Lupus Anticoagulant in F8
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Fig. 3. Lupus anticoagulant (LA) pattern with serial plasma dilutions. The normal pooled
plasma shows a straight-line pattern; by contrast, the lupus anticoagulant inhibitor line is
nonlinear, with the clotting time shortening at a greater pace with increasing dilutions.
This pattern suggests that the inhibitor effect is being diluted out. Note that the a patient
with a factor 8 inhibitor generally runs parallel to the normal pooled control, though at an
increased clotting time due to the low amount of factor 8.
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ARTICLE IN PRESSeach dilution. A positive dilute Russell viper venom test (DRVVT) will confirm the diag-
nosis of LA, but a negative DRVVT does not rule out its presence. A hexagonal phase
phospholipid neutralization (eg, StaClot LA, Diagnostica Stago, Asnieres Sur Seine,
France), platelet neutralization procedure, or other assays for LA may be needed to
confirm the presence of a LA inhibitor.30
If a patient has an antibody to a factor other than the one being assayed, it may react
with that factor which is present in the factor-deficient plasma and thereby causing
prolongation of the PT- or aPTT-based factor assay. As the patient’s plasma is diluted,
the antibody also is diluted, resulting in less interference and a gain in factor activity
with each subsequent dilution. This produces a nonlinear curve compared with the
calibration curve.
Assays for detecting specific factor inhibitors
Bethesda-type assays (or its modification, the Nijmegan assay) can be employed to
screen for inhibitors to factors.31 Although predominantly used for F8 inhibitors, these
assays can be adapted to detect any factor inhibitor. In a Bethesda assay, patient
plasma is incubated with a source of factor (usually normal pooled plasma) for 2 hours
at 37C. Residual factor activity then is measured and compared with a control
mixture. One Bethesda unit is defined as the amount of antibody that will inhibit
50% of the available factor in the normal pooled plasma. It may be necessary to dilute
the patient plasma in buffer or factor-deficient plasma before incubation to achieve
a mixture with the optimal range of 40% to 60% residual factor activity. The residual
factor activity is converted to BUs by the use of a Bethesda graph and then multiplied
by the dilution factor (see Fig. 1).31
The control mixture should mimic the patient mixture as closely as possible. If the
patient has a low titer inhibitor (less than or equal to 1 BU), the control should be
composed of normal pooled plasma and factor-deficient plasma. If the patient has
to be diluted in buffer, the control should be made using normal pooled plasma and
buffer. In the Nijmegan modification, the use of buffered normal pooled plasma stabi-
lizes the pH, permitting more accurate measurement of low-titer inhibitors. Using the
lowest possible patient dilution that gives a 40% to 60% residual factor activity
prevents overestimation of inhibitors possessing complex kinetics.
The inhibitor testing protocol is accepted widely for use in patients who have no
circulating factor activity (less than 1%). When the patient has measurable factor
activity in the sample, however, there is less agreement on protocols. Although there
is some evidence that heat-treating the plasma before incubation with normal pooled
plasma will inactivate the patient’s own factor, but not the antibody, the World Feder-
ation of Hemophilia Laboratory Manual recommends either adjusting the concentra-
tion of the control solution to match that of the patient or mathematically correcting
for the baseline factor activity of the patient.32Laboratory Evaluation of a Prolonged Prothrombin Time or Activated Partial
Thromboplastin Time
Having access to the patient’s clinical, medication, and transfusion history is one of
the best coagulation screening tests, and often may eliminate the need for mixing
studies to guide test selection.33 Is the patient actively bleeding or bruising? Is the
patient anemic? Is there any personal or family history of bleeding? If the answer to
any of these questions is yes, it makes sense to look for factor deficiencies (either
congenital or acquired) and vWD.CLL469_proof  13 June 2009  2:22 pm
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ARTICLE IN PRESSIf there is a history consistent with clotting (eg, deep vein thrombosis, pulmonary
embolism, stroke, or spontaneous abortion), or if the prolonged screening test is the
only reason for workup in an asymptomatic patient, this favors LA testing.
Medication history will reveal if the patient is receiving warfarin or heparin or another
anticoagulant such as a direct thrombin inhibitor. Does the patient have a venous
access catheter? If so, screen for heparin or consider a dilution effect. If there is an
isolated prolonged PT, one must ask: Has the patient been given vitamin K, been
on antibiotic therapy, or taken any herbal or natural therapeutics? Although most clini-
cians expect a prolonged PT/INR in vitamin K depletion, an accompanying prolonga-
tion of the aPTT may surprise them and trigger a workup for prolonged aPTT. Most
aPTT reagents are fairly sensitive to the low levels of F9 seen in vitamin K depletion,
and the decreases in factors 2 and 10. Thus, it is not unusual for the aPTT to be some-
what prolonged with warfarin or other causes of vitamin K deficiency.
One always must investigate the patient’s transfusion history. Has the patient
received any plasma, cryoprecipitate, bypassing agents, or factor concentrates? If
so, coagulation studies may be difficult to interpret. Bypassing agents contain acti-
vated F7, which can cause extremely short clotting times (and thus overestimation
of factor activity levels).
Patients may have more than one coagulopathy. For instance, combined F5/F8
deficiency is a well-characterized familial defect. These patients will present with
a prolonged PT and aPTT and usually will have bleeding symptoms when challenged.
Isolated prothrombin time elevation
Once heparin, warfarin, and other anticoagulants are ruled out, an isolated elevation of
the PT/INR likely has one of several etiologies (Table 3):
Vitamin K deficiency. The most frequent cause of an elevated PT is vitamin K defi-
ciency. Some herbal or natural products also may induce vitamin K deficiency.
Patients on antibiotics are susceptible to vitamin K deficiency, because the anti-
biotics may destroy gut bacteria that synthesize vitamin K. Because F5 is notTable 3
Isolated prothrombin time elevation (assumes that heparin, warfarin, and other anticoagulants
have been ruled out)
Differential Diagnosis Tests to Run Interpretation/Follow-up
Vitamin K deficiency
Liver disease
F7 deficiency (or inhibitor),
Lupus anticoagulant
Factors 5, 7, and LA panel
Recommend repeat draw
to verify low factor
levels
If both F5 and F7 are Y, suspect
liver involvement
If only F7 is Y, run at least one
more vitamin K-dependent
factor
If Y, suspect vitamin K deficiency
If only F7 is Y, suspect congenital
deficiency or acquired inhibitor
(rare)
Consider Bethesda assay if no
family history and recent
onset of bleeding
If lupus anticoagulant positive,
repeat in 3 months
to confirm persistence and
therefore significance
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ARTICLE IN PRESSvitamin K- dependent, assaying F5 along with one or several of the vitamin K
dependent factors will help differentiate vitamin K deficiency from liver disease.
It is helpful to be familiar with the half-lives of the various factors when interpret-
ing results of coagulation assays (see Table 2). As a rule, the shorter the half-life,
the faster the decrease in activity when starting warfarin, and the faster the
recovery of activity when discontinuing warfarin. In early vitamin K deficiency,
only the F7 may have fallen enough to prolong the PT. If inflammation is present,
acute-phase elevations of F8 and fibrinogen often keep the aPTT from prolong-
ing. Additionally, when more than one factor is decreased, the PT may prolong
more than the single factor sensitivity studies would predict.
Factor 7 deficiency. The degree of correlation between the F7 activity level and
patient bleeding varies depending on the type of tissue factor used in the F7
assay. An inhibitor to F7 is rare and is usually attributable to IgG autoantibodies.
A Bethesda-type assay can be performed to confirm the presence of an F7
inhibitor.
Lupus anticoagulant. Although more commonly associated with an elevation of the
aPTT, LA may produce an isolated elevated PT. The source of phospholipid and
phospholipid content of the PT reagent will define how sensitive the reagent is to
LA. Elevated F8 or fibrinogen may keep the aPTT from prolonging. One should
consider LA testing on any sample with unexplained prolongation of the PT.
Isolated activated partial thromboplastin time elevation
After excluding LA, the clinical picture as well as the personal, family, and medication
history (including anticoagulant therapy) will guide the workup of an isolated prolonged
aPTT (Table 4).33 With a history of bleeding, assays for F8 activity, vWD, F9, and F11
are most informative. If any factor activity level is low, one should evaluate at least
three patient dilutions for an inhibitor pattern. If any one factor shows very low activity
that does not increase with patient dilution, a Bethesda-type assay is warranted.
Patients also can have more than one disorder responsible for the prolonged aPTT
(eg, F8 deficiency or F8 inhibitor with a LA). The presence of LA also can make it chal-
lenging to monitor replacement therapy with clot-based assays. A chromogenic F8
assay may give a more accurate factor result in the presence of LA.Table 4
Isolated elevated activated partial thromboplastin time (aPTT) (assumes heparin and other
anticoagulants have been ruled out)
DifferentialDiagnosis InitialTests to Run Interpretation/Follow-Up
Von Willebrand
disease (VWD)
Factor deficiency
Factor inhibitor
Lupus
anticoagulant
(LA)
If positive history for bleeding or
bruising do F8, then F9,
then F11
If only F8 slightly Yto moderately Y,
then run von Willebrand factor
antigen and activity
If not vWD, do F8 inhibitor
If F8, F9, or F11 is markedly Y, do
Bethesda assay for that factor
If negative history for bleeding or
bruising and
 moderately [ aPTT, then do
LA, then, F8, F9, F11
 markedly [[ aPTT, then do
F12, then consider other
contact factors
If positive LA and factor activity does
not normalize with additional
dilutions, may need to do
chromogenic assay
If positive LA, repeat in 3 months to
confirm persistence and therefore
significance
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ARTICLE IN PRESSIf there is no history of bleeding, and LA is not present, assays for F12 and other
contact factors may explain the elevated aPTT.Combined elevated prothrombin time and activated partial thromboplastin time
Congenital deficiencies or acquired inhibitors of factors 2, 5, or 10 are rare. Laboratory
workup should begin with testing the common pathway factor activities, as well as LA
testing (Table 5). It is not uncommon for patients who have LA to produce antibodies
to prothrombin, and approximately 30% of these will result in a prothrombin deficiency
with some degree of bleeding. A laboratory phenomenon coined lupus cofactor effect
frequently occurs in patients who have hypothrombinemia–lupus anticoagulant
syndrome. When patient plasma is mixed with normal pooled plasma, the clotting time
(PT, aPTT, DRVVT, or LA-PTT) actually prolongs to an even greater extent. When this
phenomenon is noticed in LA testing, a F2 activity assay should be performed.
Decreased F5 activity is a good predictor of liver disease and is used commonly in
evaluating liver toxicity in acetaminophen overdose. Because F8 and fibrinogen are
acute phase reactants, they often are increased in liver disease, which may keep
the aPTT from prolonging even with decreased synthesis of F2, F5, F9, and F10.
Each laboratory’s approach to diagnosing factor deficiencies and inhibitors must be
flexible. Not all patients have well-defined coagulopathies,33 and many, especially
hospitalized patients, have more than one issue at a time. For example, patients
who have congenital or acquired hemophilia have been known to develop LA.
Workups must be conducted as efficiently and timely as possible to be of help to
the patient and clinician. Abnormal results should be verified on fresh samples (new
draws if possible), as there is ample opportunity for preanalytical error.
The laboratory approach to inherited and acquired coagulation factor deficiencies
requires active use of clinical information. The coagulation pathologist and hematolo-
gist should be familiar with the methods and capabilities of their laboratories. An
understanding of the laboratory approach to evaluating factor deficiency not onlyTable 5
Combined elevated prothrombin time and activated partial thromboplastin time (assumes heparin
and other anticoagulants have been ruled out)
Differential Diagnosis InitialTests to Run Interpretation/Follow-Up
Vitamin K deficiency
Liver disease
Disseminated intravascular
coagulation (DIC)
Lupus anticoagulant (LA)
with hypoprothrombinemia
Congenital factor deficiency
Factor inhibitor
F2, F5, and LA If only F2 Y, with 1 LA, look for
lupus cofactor effect
If LA-negative, rule out vitamin K
deficiency
Do F7 or 10 and if normal test for
F2 inhibitor
F10 If only F5 Y, do F5 inhibitor and do
F8
Rule out DIC
If only F10Y, look for evidence
of amyloidosis, respiratory
infection, and malignancy
Do F10 inhibitor
If F7 and F2 are Y but F5
is normal, likely vitamin K
deficiency/warfarin therapy
If multiple factors are Y, look for
liver disease or DIC
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ARTICLE IN PRESSwill aid clinicians in obtaining a prompt diagnosis, but also avoid pitfalls for false diag-
noses in coagulation testing.ACKNOWLEDGEMENT
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